NeoGenomics, Inc. will present new circulating tumor DNA (ctDNA) research at the 2025 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, on December 11, 2025. The company will showcase data from the SURVIVE HERoes Phase III trial and the CLEVER study, both of which used its RaDaR 1.0 assay to evaluate molecular residual disease and recurrence risk in early‑stage breast cancer patients.
The CLEVER trial presentation is scheduled for 7:00 AM–8:30 AM Central Standard Time on December 11, while the SURVIVE HERoes data will be presented later in the day. The company’s goal is to demonstrate how RaDaR‑detected ctDNA can provide actionable information to care teams monitoring patients after initial breast cancer treatment, thereby strengthening the evidence base for its liquid‑biopsy platform and supporting broader clinical adoption in community oncology settings.
NeoGenomics recently reported third‑quarter 2025 revenue of $188 million, up 12% year‑over‑year, and a net loss of $27 million, reflecting higher operating expenses and one‑time impairment charges. Gross profit margin stood at 43%, with an adjusted margin of 45%, driven by a 24% year‑over‑year increase in next‑generation sequencing (NGS) revenue. The company reaffirmed its full‑year 2025 revenue guidance of an 11%–13% increase, signaling confidence in continued demand for its core testing services.
The liquid‑biopsy market is estimated at $3–5 billion, with competitors such as Guardant Health, Foundation Medicine, and others. NeoGenomics differentiates itself through the RaDaR platform’s high sensitivity for detecting minimal residual disease and recurrence risk, positioning it as a key tool for early‑stage breast cancer monitoring. The company’s recent launch of NEO PanTracer LBx in July 2025 further expands its portfolio, targeting comprehensive genomic profiling in a growing market.
CEO Tony Zook emphasized that the findings presented at SABCS “demonstrate how RaDaR‑detected ctDNA can provide invaluable and actionable information to care teams as they monitor patients following their initial breast care treatment.” The presentation aligns with NeoGenomics’ strategy to embed MRD insights into routine oncology care and to accelerate adoption of liquid‑biopsy technology in community practices.
NeoGenomics’ strong third‑quarter earnings beat—driven by cost control and robust demand in core segments—has reinforced investor confidence in the company’s trajectory. The earnings beat, combined with the upcoming SABCS presentation, underscores NeoGenomics’ commitment to delivering clinically actionable data that can translate into revenue growth and market share gains.
The SABCS presentation is expected to reinforce NeoGenomics’ position as a leader in ctDNA diagnostics, support its broader adoption strategy, and provide a platform for future growth in the expanding liquid‑biopsy market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.